export const guidelines = {
  keySources: "The following summarized guidelines for the evaluation and management of heart failure are prepared by our editorial team based on guidelines from the American Diabetes Association (ADA 2025), the Society for Cardiovascular Angiography and Interventions (SCAI/NAEMSP/AHA/ACC/ACEP 2025), the European Society of Cardiology (ESC 2024,2023,2022,2021), the European Society of Cardiology (ESC/EACTS 2024), the Society of Cardiovascular Computed Tomography (SCCT/SVM/SCMR/SCA/AHA/ASNC/HRS/ACC/ACS 2024), and other major medical societies.",
  sections: [
    {
      title: "Diagnosis and Classification",
      id: "diagnosis",
      content: [
        {
          statement: "Heart failure is a complex clinical syndrome that results from structural or functional impairment of ventricular filling or ejection of blood.",
          level: "Class I",
          source: "AHA/ACC/HFSA 2022"
        }
      ]
    },
    {
      title: "Pharmacological Management",
      id: "pharmacology",
      content: [
        {
          statement: "ACE inhibitors or ARBs are recommended for patients with HFrEF to reduce morbidity and mortality.",
          level: "Class I",
          source: "AHA/ACC/HFSA 2022"
        }
      ]
    },
    {
      title: "Device Therapy",
      id: "devices",
      content: [
        {
          statement: "ICD therapy is recommended for primary prevention of SCD to reduce total mortality.",
          level: "Class I",
          source: "AHA/ACC/HFSA 2022"
        }
      ]
    }
  ]
}; 